Drug Trial Radar · NCT00094081
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Feb 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
861
Actual
Start
Oct 2002
Primary completion
Sep 2006
Study completion Sep 2006
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
Conditions
- Head and Neck Neoplasms
Interventions
tirapazamine (SR259075)Drug
cisplatinDrug
Radiation TherapyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Foundation for Cancer Research and Education
Phoenix, Arizona
Stanford University Medical Center
Palo Alto, California
H-Lee Moffitt Cancer Center and Research
Tampa, Florida
University of Chicago Medical Center
Chicago, Illinois
Johns Hopkins Hospital
Baltimore, Maryland
Harper Hospital
Detroit, Michigan
VA New Jersey Health Care Medical Center
East Orange, New Jersey
University of Rochester Medical Center
Rochester, New York
Medical University of South Carolina
Charleston, South Carolina
Eastern Virginia Medical School
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.